Scroll

scopolamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2424	51-34-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: scopolamine scopolamine hydrobromide hyoscine levo-duboisine scopoderm scopolamine hydrochloride scopolamine HCl	An alkaloid from SOLANACEAE, especially DATURA and SCOPOLIA. Scopolamine and its quaternary derivatives act as antimuscarinics like ATROPINE, but may have more central nervous system effects. Its many uses include an anesthetic premedication, the treatment of URINARY INCONTINENCE and MOTION SICKNESS, an antispasmodic, and a mydriatic and cycloplegic. Molecular weight: 303.36 Formula: C17H21NO4 CLOGP: 0.09 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 62.30 ALOGS: -1.66 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

scopolamine
scopolamine hydrobromide
hyoscine
levo-duboisine
scopoderm
scopolamine hydrochloride
scopolamine HCl

An alkaloid from SOLANACEAE, especially DATURA and SCOPOLIA. Scopolamine and its quaternary derivatives act as antimuscarinics like ATROPINE, but may have more central nervous system effects. Its many uses include an anesthetic premedication, the treatment of URINARY INCONTINENCE and MOTION SICKNESS, an antispasmodic, and a mydriatic and cycloplegic.

Molecular weight: 303.36
Formula: C17H21NO4
CLOGP: 0.09
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 62.30
ALOGS: -1.66
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.90	mg	O
0.90	mg	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
S (Water solubility)	666.67 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	6 %	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	4.50 hours	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	3.10 L/kg	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	27 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance)	16 mL/min/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Showing 1 to 8 of 8 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 31, 1979	FDA	NOVARTIS

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Mydriasis	102.67	15.16	43	7967	11913	63469099
Anticholinergic syndrome	90.31	15.16	26	7984	2356	63478656
Akathisia	72.23	15.16	31	7979	9115	63471897
Vomiting	37.94	15.16	155	7855	559462	62921550
Product adhesion issue	37.27	15.16	16	7994	4703	63476309
High density lipoprotein decreased	33.65	15.16	12	7998	2158	63478854
Neutrophil count increased	29.61	15.16	21	7989	16506	63464506
Infectious mononucleosis	27.36	15.16	10	8000	1929	63479083
Application site rash	24.89	15.16	10	8000	2488	63478524
Progressive multiple sclerosis	24.04	15.16	8	8002	1170	63479842

Showing 1 to 10 of 43 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neutrophil count increased	79.89	17.83	45	6088	17101	34933697
Prescription drug used without a prescription	76.05	17.83	24	6109	2130	34948668
Failure to suspend medication	64.21	17.83	15	6118	423	34950375
Neuroleptic malignant syndrome	54.98	17.83	36	6097	17898	34932900
Antipsychotic drug level increased	51.81	17.83	21	6112	3844	34946954
White blood cell count increased	50.29	17.83	48	6085	41103	34909695
Wrong patient received product	41.08	17.83	16	6117	2638	34948160
Toxicity to various agents	40.05	17.83	100	6033	200262	34750536
Accidental death	38.70	17.83	15	6118	2441	34948357
Antipsychotic drug level decreased	34.52	17.83	11	6122	1006	34949792

Showing 1 to 10 of 40 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neutrophil count increased	113.79	14.64	65	12029	29331	79702963
Mydriasis	84.76	14.64	45	12049	17598	79714696
Anticholinergic syndrome	78.82	14.64	27	12067	3584	79728710
Neuroleptic malignant syndrome	68.58	14.64	46	12048	27513	79704781
Akathisia	67.04	14.64	35	12059	13224	79719070
Vomiting	62.68	14.64	232	11862	665596	79066698
Failure to suspend medication	59.88	14.64	14	12080	460	79731834
White blood cell count increased	56.58	14.64	63	12031	74570	79657724
Differential white blood cell count abnormal	55.15	14.64	18	12076	2059	79730235
Antipsychotic drug level increased	52.38	14.64	23	12071	5934	79726360

Showing 1 to 10 of 69 entries

Previous1 2 3 4 5 6 7Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A04AD01	ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS ANTIEMETICS AND ANTINAUSEANTS Other antiemetics
ATC	A04AD51	ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS ANTIEMETICS AND ANTINAUSEANTS Other antiemetics
ATC	N05CM05	NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Other hypnotics and sedatives
ATC	S01FA02	SENSORY ORGANS OPHTHALMOLOGICALS MYDRIATICS AND CYCLOPLEGICS Anticholinergics
CHEBI has role	CHEBI:25212	metabolites
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:48876	muscarinic antagonists
CHEBI has role	CHEBI:50513	mydriatics
CHEBI has role	CHEBI:50919	antiemetico
CHEBI has role	CHEBI:53784	antispasmodics

Showing 1 to 10 of 24 entries

Previous1 2 3Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Vasomotor rhinitis	indication	8229003	DOID:4730
Irritable bowel syndrome	indication	10743008	DOID:9778
Peptic ulcer	indication	13200003	DOID:750
Motion sickness	indication	37031009	DOID:2951
Dilated pupil	indication	37125009
Cough	indication	49727002
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Cycloplegia	indication	68158006	DOID:10033
Nasal congestion	indication	68235000

Showing 1 to 10 of 107 entries

Previous1 2 3 4 5…11Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.24	acidic
pKa2	7.95	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	Ki	9	WOMBAT-PK	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	8.86	WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	9.40	WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	9.37	WOMBAT-PK
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	7.75	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR		ACM2_RAT		Kd	8.52	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR		ACM1_RAT		Ki	9.28	CHEMBL
Muscarinic acetylcholine receptor M3	GPCR		ACM3_RAT		Kd	9.19	CHEMBL
Muscarinic receptor M1	GPCR		Q8WMX0_BOVIN		Ki	9.39	CHEMBL
Muscarinic acetylcholine receptor DM1	GPCR		ACM1_DROME		Ki	9.15	CHEMBL

Showing 1 to 10 of 11 entries

Previous1 2Next

External reference:

Show entries

Search:

ID	Source
001719	NDDF
003458	NDDF
1472	MMSL
3000322	PUBCHEM_CID
330	IUPHAR_LIGAND_ID
387409009	SNOMEDCT_US
387477005	SNOMEDCT_US
4018399	VANDF
4018401	VUID
4018401	VANDF

Showing 1 to 10 of 30 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Belladonna Alkaloids with Phenobartbital	HUMAN PRESCRIPTION DRUG LABEL	4	0440-7183	TABLET	0.01 mg	ORAL	UNAPPROVED DRUG OTHER	14 sections
Belladonna Alkaloids with Phenobartbital	HUMAN PRESCRIPTION DRUG LABEL	4	21695-890	TABLET	0.01 mg	ORAL	Unapproved drug other	15 sections
Donnatal	HUMAN PRESCRIPTION DRUG LABEL	4	17856-0423	ELIXIR	0.01 mg	ORAL	unapproved drug other	12 sections
Donnatal	HUMAN PRESCRIPTION DRUG LABEL	4	42254-268	TABLET	0.01 mg	ORAL	Unapproved drug other	15 sections
Donnatal	HUMAN PRESCRIPTION DRUG LABEL	4	42291-245	TABLET	0.01 mg	ORAL	unapproved drug other	22 sections
PHENOBARBITAL WITH BELLADONNA ALKALOIDS	HUMAN PRESCRIPTION DRUG LABEL	4	17856-0162	ELIXIR	0.01 mg	ORAL	unapproved drug other	16 sections
PHENOBARBITAL WITH BELLADONNA ALKALOIDS	HUMAN PRESCRIPTION DRUG LABEL	4	42291-205	ELIXIR	0.01 mg	ORAL	unapproved drug other	17 sections
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate and Scopolamine Hydrobromide	Human Prescription Drug Label	4	50742-667	TABLET	0.01 mg	ORAL	UNAPPROVED DRUG OTHER	20 sections
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide	Human Prescription Drug Label	4	50742-665	ELIXIR	0.01 mg	ORAL	UNAPPROVED DRUG OTHER	20 sections
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide	Human Prescription Drug Label	4	50742-665	ELIXIR	0.01 mg	ORAL	UNAPPROVED DRUG OTHER	20 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next